600521 华海药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.35413.18410.63116.558--
总资产报酬率 ROA (%)1.9725.7594.5196.947--
投入资产回报率 ROIC (%)2.3106.7995.3678.262--

边际利润分析
销售毛利率 (%)63.32161.91060.42362.36460.004
营业利润率 (%)11.98415.40513.53418.71813.071
息税前利润/营业总收入 (%)14.18116.33014.89518.12414.678
净利润/营业总收入 (%)8.97111.6009.83614.2287.235

收益指标分析
经营活动净收益/利润总额(%)94.806107.179110.133108.02943.574
价值变动净收益/利润总额(%)3.796-6.710-14.805-4.63956.798
营业外收支净额/利润总额(%)0.296-0.491-2.201-2.536-10.353

偿债能力分析
流动比率 (X)1.5611.4201.4001.648--
速动比率 (X)0.9310.8480.7690.945--
资产负债率 (%)52.95255.48255.63957.328--
带息债务/全部投入资本 (%)39.66443.13843.06343.999--
股东权益/带息债务 (%)136.750120.051119.208112.754--
股东权益/负债合计 (%)88.00779.15278.04672.520--
利息保障倍数 (X)6.56316.3299.017-138.2855.182

营运能力分析
应收账款周转天数 (天)121.768102.260111.49498.3230.000
存货周转天数 (天)380.646338.832372.598353.7140.000